tirzepatide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42383207
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.
Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.
- 저자
- Atul Malhotra, Daniel J Gottlieb, Vaishnavi Kundel, Holger Woehrle, Sujatro Chakladar, Livia Firmino Goncalves
- 저널
- Contemporary clinical trials communications
- 공개일
- 2026 Aug
- 연구 유형
- 기타
- DOI
- 10.1016/j.conctc.2026.101660
문헌 요약
Obstructive sleep apnea (OSA) is highly prevalent, yet current treatment remains limited. Poor adherence to positive airway pressure (PAP) and barriers associated with injectable therapies can limit potential therapeutic options for moderate-to-severe OSA. The SURMOUNT-OSA trials demonstrated that tirzepatide contributes to OSA severity improvements; howe…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.